CN112022816A - 一种吡拉西坦片及其制备方法 - Google Patents
一种吡拉西坦片及其制备方法 Download PDFInfo
- Publication number
- CN112022816A CN112022816A CN202010759932.XA CN202010759932A CN112022816A CN 112022816 A CN112022816 A CN 112022816A CN 202010759932 A CN202010759932 A CN 202010759932A CN 112022816 A CN112022816 A CN 112022816A
- Authority
- CN
- China
- Prior art keywords
- piracetam
- starch
- minutes
- starch slurry
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 title claims abstract description 101
- 229960004526 piracetam Drugs 0.000 title claims abstract description 99
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 229920002472 Starch Polymers 0.000 claims abstract description 104
- 239000008107 starch Substances 0.000 claims abstract description 104
- 235000019698 starch Nutrition 0.000 claims abstract description 104
- 239000002002 slurry Substances 0.000 claims abstract description 59
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 44
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 22
- 239000000853 adhesive Substances 0.000 claims abstract description 11
- 230000001070 adhesive effect Effects 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 238000007873 sieving Methods 0.000 claims description 30
- 238000003756 stirring Methods 0.000 claims description 28
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 24
- 238000001035 drying Methods 0.000 claims description 20
- 239000004677 Nylon Substances 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 18
- 229920001778 nylon Polymers 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 16
- 238000009835 boiling Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 238000007599 discharging Methods 0.000 claims description 10
- 238000007580 dry-mixing Methods 0.000 claims description 10
- 239000007779 soft material Substances 0.000 claims description 10
- 238000003825 pressing Methods 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 4
- 230000000052 comparative effect Effects 0.000 description 21
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 19
- 239000000523 sample Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000000945 filler Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- NHNHWBFFDARHFO-UHFFFAOYSA-N 2-(1h-pyrrol-2-yl)acetamide Chemical compound NC(=O)CC1=CC=CN1 NHNHWBFFDARHFO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- HCDOKWSJBSUZRC-UHFFFAOYSA-N N(C(=O)C)C=1C(N=CC=1)=O Chemical compound N(C(=O)C)C=1C(N=CC=1)=O HCDOKWSJBSUZRC-UHFFFAOYSA-N 0.000 description 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 231100000076 Toxic encephalopathy Toxicity 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- UKGWLQJQMORIHS-UHFFFAOYSA-N acetic acid;pyrrolidin-2-one Chemical compound CC(O)=O.O=C1CCCN1 UKGWLQJQMORIHS-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
原辅料名称 | 每1万片用量 | 重量份数 |
吡拉西坦 | 4kg | 1000 |
淀粉 | 0.4kg | 100 |
6%淀粉浆 | 0.9kg | 225 |
硬脂酸镁 | 14g | 0.35 |
十二烷基硫酸钠 | 14g | 0.35 |
原辅料名称 | 每1万片用量 | 重量份数 |
吡拉西坦 | 4kg | 1000 |
淀粉 | 0.4kg | 100 |
6%淀粉浆 | 0.92kg | 230 |
硬脂酸镁 | 14g | 0.35 |
十二烷基硫酸钠 | 14g | 0.35 |
原辅料名称 | 每1万片用量 | 重量份数 |
吡拉西坦 | 4kg | 1000 |
淀粉 | 0.4kg | 100 |
6%淀粉浆 | 0.96kg | 240 |
硬脂酸镁 | 16g | 0.4 |
十二烷基硫酸钠 | 14g | 0.35 |
原辅料名称 | 每1万片用量 | 重量份数 |
吡拉西坦 | 4kg | 1000 |
淀粉 | 0.4kg | 100 |
6%淀粉浆 | 0.84kg | 210 |
硬脂酸镁 | 12g | 0.3 |
十二烷基硫酸钠 | 14g | 0.35 |
原辅料名称 | 每1万片用量 | 重量份数 |
吡拉西坦 | 4kg | 1000 |
淀粉 | 0.4kg | 100 |
6%淀粉浆 | 0.86kg | 215 |
硬脂酸镁 | 13.6g | 0.32 |
十二烷基硫酸钠 | 14g | 0.35 |
对比例 | 填充剂 | 重量份数 |
对比例1-1 | 微晶纤维素 | 100 |
对比例1-2 | 蔗糖 | 100 |
对比例1-3 | 甘露醇 | 100 |
对比例1-4 | 乳糖 | 100 |
对比例 | 粘合剂 | 重量份数 |
对比例2-1 | 3%淀粉浆 | 1.68Kg |
对比例2-2 | 4%淀粉浆 | 1.26Kg |
对比例2-3 | 8%淀粉浆 | 0.63Kg |
对比例 | 粘合剂 | 重量份数 |
对比例3-1 | 水 | 0.84Kg |
对比例3-2 | 40%乙醇水 | 0.84Kg |
对比例3-3 | 2%羟丙基纤维素溶液 | 0.84Kg |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010759932.XA CN112022816B (zh) | 2020-07-31 | 2020-07-31 | 一种吡拉西坦片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010759932.XA CN112022816B (zh) | 2020-07-31 | 2020-07-31 | 一种吡拉西坦片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112022816A true CN112022816A (zh) | 2020-12-04 |
CN112022816B CN112022816B (zh) | 2022-08-12 |
Family
ID=73583739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010759932.XA Active CN112022816B (zh) | 2020-07-31 | 2020-07-31 | 一种吡拉西坦片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112022816B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002104966A (ja) * | 2000-09-29 | 2002-04-10 | Dai Ichi Seiyaku Co Ltd | ネフィラセタム含有経口固形製剤 |
RU2205631C1 (ru) * | 2002-06-19 | 2003-06-10 | Закрытое акционерное общество "Брынцалов-А" | Ноотропное средство "ноотобрил" в форме таблеток |
WO2009084017A2 (en) * | 2007-10-10 | 2009-07-09 | Rubicon Research Private Limited | Taste-masked orally disintegrating tablets of memantine hydrochloride |
CN102125524A (zh) * | 2010-01-16 | 2011-07-20 | 青岛科技大学 | 一种吡拉西坦口腔崩解片 |
CN104546682A (zh) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | 一种吡拉西坦组合物冻干片及其制备方法 |
CN110384666A (zh) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | 一种湿法制粒压片制备右旋奥拉西坦片剂的方法 |
CN111297818A (zh) * | 2020-04-02 | 2020-06-19 | 常州制药厂有限公司 | 一种高载药量吡拉西坦片剂组合物及其制备方法 |
CN111346066A (zh) * | 2020-03-17 | 2020-06-30 | 乐普药业(北京)有限责任公司 | 含吡拉西坦的缓释制剂 |
-
2020
- 2020-07-31 CN CN202010759932.XA patent/CN112022816B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002104966A (ja) * | 2000-09-29 | 2002-04-10 | Dai Ichi Seiyaku Co Ltd | ネフィラセタム含有経口固形製剤 |
RU2205631C1 (ru) * | 2002-06-19 | 2003-06-10 | Закрытое акционерное общество "Брынцалов-А" | Ноотропное средство "ноотобрил" в форме таблеток |
WO2009084017A2 (en) * | 2007-10-10 | 2009-07-09 | Rubicon Research Private Limited | Taste-masked orally disintegrating tablets of memantine hydrochloride |
CN102125524A (zh) * | 2010-01-16 | 2011-07-20 | 青岛科技大学 | 一种吡拉西坦口腔崩解片 |
CN104546682A (zh) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | 一种吡拉西坦组合物冻干片及其制备方法 |
CN110384666A (zh) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | 一种湿法制粒压片制备右旋奥拉西坦片剂的方法 |
CN111346066A (zh) * | 2020-03-17 | 2020-06-30 | 乐普药业(北京)有限责任公司 | 含吡拉西坦的缓释制剂 |
CN111297818A (zh) * | 2020-04-02 | 2020-06-19 | 常州制药厂有限公司 | 一种高载药量吡拉西坦片剂组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
陆依华等: "氯雷他定片剂一致性评价研究方法", 《药学进展》 * |
黄涵琦等: "优化吡拉西坦片工艺,提高其崩解时限及脆碎度", 《黑龙江医药》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112022816B (zh) | 2022-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09508913A (ja) | 微粉化ネビボロールを含有する組成物 | |
CN105640913B (zh) | 一种奥美沙坦酯片及其制备方法 | |
CN111821289B (zh) | 一种利鲁唑口崩片及其制备方法 | |
CN107167401B (zh) | 左乙拉西坦缓释片药物组合物及其质控和制法 | |
CN112022816B (zh) | 一种吡拉西坦片及其制备方法 | |
CN110934833B (zh) | 一种复方氨酚那敏颗粒 | |
CN117562900A (zh) | 具有明显临床优势的阿哌沙班新制剂组合物及其制备方法 | |
CN106018618B (zh) | 草酸艾司西酞普兰片剂组合物和质控方法 | |
CN115154431B (zh) | 一种硝酸甘油片剂及其制备方法 | |
CN113350304B (zh) | 一种非甾体抗炎类缓释制剂及其制备方法 | |
CN107982237B (zh) | 一种盐酸索他洛尔制剂及其制备方法 | |
CN107174571B (zh) | 一种利格列汀及其盐、酯、衍生物的药物组合物及其制备方法 | |
CN113209036B (zh) | 一种阿齐沙坦片及其制备方法和应用 | |
CN106580909B (zh) | 一种含有盐酸沙格雷酯固体药物组合物 | |
CN111000812B (zh) | 一种拉考沙胺片的制备方法 | |
CN112386578A (zh) | 一种孟鲁司特钠咀嚼片及其制备方法 | |
CN114652696A (zh) | 一种盐酸西替利嗪片及其制备方法 | |
CN113730369A (zh) | 一种阿哌沙班片剂组合物及其制备方法 | |
CN109419780B (zh) | 一种盐酸索他洛尔片剂及其制备方法 | |
CN111991359B (zh) | 一种安乃近片及其制备方法 | |
CN117338733B (zh) | 一种富马酸替诺福韦二吡呋酯片及其制备工艺 | |
CN115844847B (zh) | 一种盐酸伊托必利制剂及其制备方法 | |
CN109985013B (zh) | 一种尼群地平分散片及其制备方法 | |
CN117045610B (zh) | 一种溶出高稳定性的盐酸拉贝洛尔组合物及其制备方法 | |
CN112535674B (zh) | 一种来曲唑片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: No.47 Zhongxing Street, Lincheng Economic Development Zone, Xingtai City, Hebei Province 054300 Applicant after: HEBEI JUNLIN PHARMACEUTICAL Co.,Ltd. Address before: 054300 North Ring East Road, Lincheng Town, Lincheng County, Xingtai City, Hebei Province Applicant before: HEBEI JUNLIN PHARMACEUTICAL Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Piracetam Tablet and Its Preparation Method Effective date of registration: 20230907 Granted publication date: 20220812 Pledgee: Hebei Lincheng Rural Commercial Bank Co.,Ltd. Pledgor: HEBEI JUNLIN PHARMACEUTICAL CO.,LTD. Registration number: Y2023980055796 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231228 Granted publication date: 20220812 Pledgee: Hebei Lincheng Rural Commercial Bank Co.,Ltd. Pledgor: HEBEI JUNLIN PHARMACEUTICAL CO.,LTD. Registration number: Y2023980055796 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Piracetam Tablet and Its Preparation Method Effective date of registration: 20231229 Granted publication date: 20220812 Pledgee: Hebei Lincheng Rural Commercial Bank Co.,Ltd. Pledgor: HEBEI JUNLIN PHARMACEUTICAL CO.,LTD. Registration number: Y2023980075614 |